Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIT: Multiple Electrolytes vs Normal Saline in Hemorrhagic Stroke
NCT06374823Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- May 2024
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- Capital Medical University
- Modality
- Small Molecules
- Conditions
- hemorrhagic stroke
01
Overview
Phase 4, randomised, open-label trial of Multiple Electrolytes Injection (II) in hemorrhagic stroke (2 arms), sponsored by Capital Medical University. Primary endpoint: Incidence of Hyperchloremia at 72 hours. Planned start May 2024; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Multiple Electrolyte
Multiple Electrolytes Injection (II) for 72 hours
Normal Saline
Sodium Chloride injection for 72 hours
03
Who it enrols
Adult patients with hemorrhagic stroke requiring fluid therapy, excluding those with preexisting hyperchloremia, organ failure, or needing routine RRT.
04
Endpoints
Primary
Incidence of Hyperchloremia
Secondary
Hyperchloremic acidosis
Plasma osmolality
Acute Kidney Injury
Renal Replacement Therapy
Hospital Length of Stay
ICU Length of Stay
Hospitalization expense
Beyond the preview
Go deeper on NCT06374823.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374823.